Blood tests show potential for early cancer detection years before diagnosis

Recent scientific research highlights the growing potential of using blood-based tests for the early detection and monitoring of cancer. A longitudinal study involving the Ontario Health Study, conducted by researchers from the University of Toronto, the Ontario Institute for Cancer Research, and the University of Oxford, found that epigenetic alterations and cell-free DNA signatures can appear in blood plasma up to eight years before a clinical cancer diagnosis.

The study, published in Cell Genomics, noted that these molecular warning signs were particularly strong in prostate cancer patients. While breast cancer markers also showed predictability, they varied more significantly across subtypes and age groups.

In a separate clinical development, Cork University Hospital is launching the Melody trial. This two-year initiative, led by Dr. Emer Lynch, investigates the use of liquid biopsies—simple blood draws—as a less invasive alternative to traditional tissue biopsies for identifying genetic characteristics in advanced breast cancers. This approach aims to provide clinicians with genetic data to personalize treatments and monitor patient responses more effectively.

Additionally, research from the University of Oxford suggests that analyzing patterns in routine blood tests over time, rather than looking at isolated results, can help identify patients with unexplained weight loss who may be at higher risk for cancer.